Attorney Docket No.: 02481.1771-00 Application No.: 10/021,502

with only one ( $C_0$ - $C_{30}$ )alkylene-(LAG) radical, LAG being a sugar residue, disugar residue, trisugar residue, tetrasugar residue, a sugar acid or an amino sugar, classified 514, subclass 25;

- Group XXII Claims 16-17, drawn to methods for the treatment of an arteriosclerotic manifestation, using compounds of the Formula I with only one (C<sub>0</sub>-C<sub>30</sub>)alkylene-(LAG) radical, LAG being an amino acid residue or an oligopeptide residue, classified in class 514, subclass 2<sup>+</sup>;
- Group XXIII Claims 16-17, drawn to methods for the treatment of an arteriosclerotic manifestation, using compounds of the Formula I with only one (C<sub>0</sub>-C<sub>30</sub>)alkylene-(LAG) radical, LAG being a trialkylammoniumalkyl radical, classified in class 514, subclass 210.02;
- Group XXIV Claims 16-17, drawn to methods for the treatment of an arteriosclerotic manifestation, using compounds of the Formula I with only one (C<sub>0</sub>-C<sub>30</sub>)alkylene-(LAG) radical, LAG being -O-(SO<sub>2</sub>)-OH, classified in class 514, subclass 210.02; and
- **Group XXV** Claims 16-17, drawn to methods for the treatment of an arteriosclerotic manifestation, using compounds of the Formula I with only one (C<sub>0</sub>-C<sub>30</sub>)alkylene-(LAG) radical, classified in class 514, subclass 210.02.

## REMARKS

The restriction requirement is respectfully traversed. However, to be fully responsive, Applicants elect, with traverse, the subject matter of Group I, claims 1-3, 4 and 5-8 without prejudice.

The Examiner has also identified what the Examiner characterizes as patentably distinct species in each of Groups I, II, III, and IV, and required an election of a single disclosed species for prosecution on the merits, to which the claims shall be restricted if no generic claim is ultimately held to be allowable. In response, Applicants elect as the species the compound wherein R3 or R4 is the distinct location for the

FINNEGAN HENDERSON FARABOW GARRETT & DUNNERLLP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com

Attorney Docket No.: 02481.1771-00

Application No.: 10/021,502

 $(C_0-C_{30})$ alkylene-(LAG) radical (Option "B"), and the  $(C_0-C_{30})$ alkylene is the patentably distinct linker found in Example 1. At least claims 1-3, 4 and 5-8 read on the elected invention.

Moreover, with respect to the election of species requirement, Applicants note that the election was made with the understanding that, if the elected species is found allowable, the Examiner will continue to examine the full scope of the pending claims to the extent necessary to determine the patentability of these pending claims, i.e., extending the search to a reasonable number of the non-elected species, as is the duty according to M.P.E.P. § 803.02 and 35 U.S.C. § 121.

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,

Dated: June 30, 2003

Carol P. Einaudi

Reg. No. 32,220

FINNEGAN **HENDERSON** FARABOW GARRETT & DUNNER₩

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com